Jennifer Mihas ta kasance tana jagorantar salon rayuwa, wasan tennis da yawo a Seattle.Amma a cikin Maris 2020, ta gwada inganci don COVID-19 kuma tun daga lokacin ba ta da lafiya.Ya zuwa yanzu ta gaji da tafiya ɗaruruwan yadi, kuma ta yi fama da ƙarancin numfashi, ciwon kai, ciwon kai da sauran alamun da ke damun ta.
Waɗannan ba lokuta na musamman ba ne.A cewar Cibiyar Kula da Cututtuka da Cututtuka ta Amurka, kashi 10 zuwa 30 na mutanen da suka kamu da cutar ta SARS-CoV-2 suna fuskantar matsalolin lafiya na dogon lokaci.Yawancin su kamar Mihas, waɗannan alamomin dagewa, waɗanda aka sani da mummunan sakamako na kamuwa da cuta ta SARS-CoV-2 (PASC) ko, galibi, abubuwan da ke faruwa na dogon lokaci na COVID-19, na iya zama mai laushi ko mai ƙarfi isa ya zama nakasa, yana shafar kusan kowane tsarin gabobin jiki.
Mutanen da abin ya shafa sukan bayar da rahoton matsananciyar gajiya da ciwon jiki.Mutane da yawa sun rasa jin daɗin ɗanɗanonsu ko ƙamshinsu, kwakwalwarsu tana raguwa kuma ba za su iya tattarawa ba, wannan matsala ce ta gama gari.Masana sun damu cewa wasu marasa lafiya da ke da dogon lokaci na COVID-19 na iya taɓa murmurewa.
Yanzu, abubuwan da ke faruwa na dogon lokaci na COVID-19 suna karuwa a cikin tabo.A watan Fabrairu, Cibiyar Lafiya ta NATIONAL ta ba da sanarwar wani shiri na dala biliyan 1.15 don tantance musabbabin dogon lokaci na COVID-19 da nemo hanyoyin rigakafi da magance cutar.
Ya zuwa karshen watan Yuni, sama da mutane miliyan 180 ne suka gwada ingancin SARS-CoV-2, kuma daruruwan miliyoyi na iya kamuwa da cutar ta SARS-CoV-2, tare da samar da sabbin magunguna don magance adadi mai yawa. yiwu sabon alamu a magani.
Kiwon lafiya na PureTech yana gudanar da gwaji na asibiti na kashi II na nau'in pirfenidone da aka yanke, LYT-100.An amince da Pirfenidone don fibrosis na huhu na idiopathic.Lyt-100 yana kaiwa ga cytokines masu kumburi, ciki har da IL-6 da TNF-α, kuma yana rage siginar TGF-β don toshe ƙaddamarwar collagen da samuwar tabo.
CytoDyn tana gwada CC motactic chemokine receptor 5 (CCR5) antagonist leronlimab, wani ɗan adam IgG4 monoclonal antibody, a cikin gwajin lokaci na 2 na mutane 50.CCR5 yana shiga cikin matakai masu yawa na cututtuka, ciki har da HIV, mahara sclerosis, da ciwon daji na metastatic.An gwada Leronlimab a cikin gwajin asibiti na lokaci 2B/3 azaman ƙarin magani don cututtukan numfashi a cikin marasa lafiya masu fama da COVID-19.Sakamakon ya nuna cewa miyagun ƙwayoyi yana da fa'idar rayuwa idan aka kwatanta da jiyya da aka saba amfani da su, kuma nazarin lokaci na 2 na yanzu zai bincika miyagun ƙwayoyi a matsayin magani ga cututtuka masu yawa.
Ampio Pharmaceuticals ya ba da rahoton sakamako mai kyau na lokaci na 1 don cyclopeptide LMWF5A (aspartic alanyl diketopiperazine), wanda ke magance ƙumburi mai yawa a cikin huhu, kuma Ampio ya yi iƙirarin cewa peptide ya ƙara yawan mace-mace a cikin marasa lafiya da damuwa na numfashi.A cikin sabon gwajin Mataki na 1, marasa lafiya da alamun numfashi na tsawon makonni huɗu ko fiye za a gudanar da su a gida tare da nebulizer na tsawon kwanaki biyar.
Synairgen a cikin United Kingdom sun yi amfani da irin wannan hanyar don ƙara abubuwan COVID-19 na dogon lokaci zuwa gwaji na asibiti na 3 na SNG001 (inhaled IFN-β).Sakamako daga nazarin lokaci na 2 na miyagun ƙwayoyi ya nuna cewa SNG001 yana da amfani ga inganta haƙuri, farfadowa, da fitarwa idan aka kwatanta da placebo a ranar 28.
Lokacin aikawa: 26-08-21